Recent Updates
Recently added Catalysts

PROCRIT

Phase 2

Anemia | Small molecule | Hematology |Johnson & Johnson|Last Updated: Jun 10, 2011

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedUNCONTROLLED
Total Trials1
Total Enrollment186

FDA Designations

No designations recorded

Clinical trial landscape

PROCRIT · 1 trial · 1 indication

Phase 2 1
NCT00210600Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving ChemotherapyAnemia
COMPLETED186 Analytics
PHASE2COMPLETED
Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy
Anemia
NCT00210600186
Unlock trial analytics

Study Endpoints

Primary Endpoints

The proportion of weekly hemoglobin levels for all patients in each group during the 16 week PROCRIT (Epoetin alfa) treatment that are > 11.0 g/dL and < 13.0 g/dL.

Secondary Endpoints

The proportion of patients in the early intervention group for whom all hemoglobin values during the 16 week PROCRIT (Epoetin alfa) treatment were > 11.0 g/dL and < 13.0 g/dL.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
PROCRIT (Epoetin alfa)DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Biopsy confirmed diagnosis of non-myeloid malignancy * Baseline hemoglobin (Hb) value of \>= 11.0 g/dL and \<= 12.0 g/dL * No blood transfusions in the 28 days prior to the start of Treatment Phase * Must be receiving chemotherapy or will begin receiving chemotherapy at start ...

Unlock Eligibility Criteria

Competitive Landscape -Anemia 17 trials

CompanyTickerTrialsLead PhaseDrugs
Bristol-Myers Squibb CompanyBMY2PHASE3ACE-536
Akebia Therapeutics, Inc.AKBA3PHASE3Erythropoiesis-Stimulating Agent, Vadadustat
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK1PHASE3Elritercept, Epoetin Alfa
Cerus CorporationCERS1PHASE3Undisclosed
Disc Medicine, Inc.IRON2PHASE2DISC-0974
Incyte CorporationINCY1PHASE1INCB000928, ruxolitinib
Sunshine Biopharma IncorporatedSBFM1PHASE2SSS06, rhEPO
Ascentage Pharma Group International Unsponsored ADRAAPG1PHASE1APG-5918
Unlock Competitive Intelligence

Frequently asked questions about PROCRIT

What is PROCRIT used for?

PROCRIT is used for anemia, specifically in patients receiving chemotherapy. It is an investigational small molecule being studied in hematology. The drug is being evaluated for its ability to manage anemia in this patient population.

Who makes PROCRIT?

PROCRIT is being developed by Johnson & Johnson, a company traded under the ticker JNJ. The drug is currently in Phase 2 clinical development for the treatment of anemia.

What phase is PROCRIT in?

PROCRIT is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for its safety and efficacy in treating anemia.

What clinical trials is PROCRIT in?

PROCRIT has one completed clinical trial, NCT00210600, titled 'Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy.' This Phase 2 trial enrolled 186 participants with anemia.

Is PROCRIT the same as Epoetin Alfa?

Yes, PROCRIT is also known as Epoetin Alfa. The clinical trial NCT00210600 refers to PROCRIT as Epoetin Alfa, indicating that these names refer to the same drug being studied for anemia.